# NP28761 (NCT01871805)

> A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: alectinib
- Indication: ALK-positive crizotinib-resistant non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01871805
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Alectinib
- Enrollment: 134
- Primary outcome: Number of Participants With Dose Limiting Toxicities (DLTs): Phase I
- Primary outcome: Recommended Phase II Dose (RP2D): Phase I
- Primary outcome: Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Independent Review Committee (IRC): Phase II

## Indexed commentary on NP28761 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=np28761-nct01871805